Clinical benefit may result from the study of T cells specific for bacterial metabolic products, CD8+ T cells that recognize HLA-E or class II molecules and can potentially cure SIV or TB, and T cells that recognize specific lipids presented by CD1. Here, HLA-E is linked to tuberculosis.